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Abstract
Background: Male infertility is a common cause of reproductive failure in humans. In mice, targeted deletions of
the genes coding for FKBP6 or FKBP52, members of the FK506 binding protein family, can result in male infertility.
In the case of FKBP52, this reflects an important role in potentiating Androgen Receptor (AR) signalling in the
prostate and accessory glands, but not the testis. In infertile men, no mutations of FKBP52 or FKBP6 have been
found so far, but the gene for FKBP-like (FKBPL) maps to chromosome 6p21.3, an area linked to azoospermia in a
group of Japanese patients.
Methods: To determine whether mutations in FKBPL could contribute to the azoospermic phenotype, we
examined expression in mouse and human tissues by RNA array blot, RT-PCR and immunohistochemistry and
sequenced the complete gene from two azoospermic patient cohorts and matching control groups. FKBPL-AR
interaction was assayed using reporter constructs in vitro.
Results: FKBPL is strongly expressed in mouse testis, with expression upregulated at puberty. The protein is
expressed in human testis in a pattern similar to FKBP52 and also enhanced AR transcriptional activity in reporter
assays. We examined sixty patients from the Japanese patient group and found one inactivating mutation and one
coding change, as well as a number of non-coding changes, all absent in fifty-six controls. A second, Irish patient
cohort of thirty showed another two coding changes not present in thirty proven fertile controls.
Conclusions: Our results describe the first alterations in the gene for FKBPL in azoospermic patients and indicate a
potential role in AR-mediated signalling in the testis.
Background
Genetic causes are thought to account for 10-15% of
cases of severe male infertility [1]. Azoospermia is most
commonly associated with microdeletions of the AZF
gene on the Y chromosome [2,3], but mutations in the
androgen receptor (AR) gene [4], important for sex hor-
mone signalling, are also associated with this phenotype.
Known mutations in these and other genes still only
account for a fraction of azoospermia cases, suggesting
that other genetic causes remain to be discovered.
Androgen insensitivity syndrome (AIS) can result in a
variety of defects in the affected patient, including gyne-
comastia, cryptorchidism and hypospadias. Mild AIS
(MAIS) on the other hand can have infertility as the
only symptom and patients often show no mutations in
the AR gene [5]. Defects in AR coactivators have already
been implicated in one case of complete androgen resis-
tance in humans [6] and in two sisters with partial resis-
tance to multiple steroid hormones [7]. Homozygous
deletion of the AR cochaperone FK506 binding protein
52 (FKBP52) in mice has been shown independently by
two groups to result in male infertility and hypospadias
with underdevelopment of the prostate and seminal
vesicles [8,9]. Both groups found evidence for
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compromised AR activity in the knockout mice, and
showed that FKBP52 potentiates AR signalling in
response to androgen in prostate cell lines. Though the
testes in the FKBP52 knockout mice were normal, cell
type-specific AR deletions in mice have shown a
requirement for the receptor in Sertoli cells during nor-
mal spermatogenesis [10,11]. This suggests that another
AR cochaperone might exist in the testis which is
required for optimal AR activity in these cells.
FK506 binding protein-like (FKBPL, aka DIR-1 and
WISp39) was first described as a radioresponsive gene
[12] and is a less well-characterised member of the
FKBP family. It demonstrates binding to heat shock pro-
tein 90 (HSP90) through its conserved tetratricopeptide
(TPR) repeats [13] and more recently it has been shown
to interact with and stimulate the activity of the gluco-
corticoid receptor (GR) in human cell lines [14]. The
PPI domain of FKBPL lacks crucial catalytic residues
needed for the isomerase activity seen in other family
members like FKBP6, which alters target protein confor-
mation and helps regulate assembly of multiprotein
complexes for clients such as ryanodine receptor and
mTOR [15]. FKBP52 has one functional PPI domain,
but catalytic activity may not actually be required for
FKBP52-mediated regulation of AR function [16].
FKBPL maps to human chromosome 6p21.3: linkage
studies in a Japanese population [17] implicate this
region specifically in azoospermia (LOD score 3.5, p =
0.0005). The region contains a large number of genes,
some of which were excluded by candidate studies [18].
There are also three cases of chromosomal breakpoints
in this region leading to infertility in azoospermic males
on the Mendelian Cytogenetics Network database, with
two of these listed as azoospermic [19]. A separate
report describes a family where six members carry a
6p21 translocation and show male-only (n = 3) infertility
and azoospermia [20].
We examined FKBPL expression in mouse and human
tissues and sequenced DNA from two human azoosper-
mic patient cohorts, finding alterations in the gene.
Furthermore, we provide evidence that FKBPL can
increase transcription of AR targets in response to
androgen and that the altered proteins seen in patients
may be deficient in this activity.
Methods
Subjects
Patient samples were obtained with informed consent
and approved for screening by the Ethical Approval
committees of the respective institutes. The cohort of
azoospermic patients from Osaka University, Japan, have
been previously described and patients showing obstruc-
tive azoospermia or chromosomal abnormalities were
excluded [17]: DNA from a control group of healthy
Japanese males was obtained from the same source. The
thirty azoospermic patient samples from Human
Assisted Reproduction Ireland, Rotunda Hospital,
Dublin, Ireland showed no Y chromosome microdele-
tions or chromosome abnormalities: the control group
here were thirty proven fertile males [21]. Obstructive
azoospermia was excluded for both patient groups.
Mice
Tissues were collected from Swiss/To (Harlan, UK)
mice, which were maintained in accordance with the
Home Office regulations under project licence to CPW.
Analysis of Fkbpl mRNA expression by RT-PCR
Total RNA was extracted using the RNeasy Mini Kit,
including the optional DNAse treatment, following the
manufacturer’s instructions (Qiagen, Crawley, UK) and
1 μg used to make cDNA in a 12.5 μl mixture contain-
ing 10 mM Tris HCL (pH 8.3), 0.2 μg Oligo(dT)15
primer (Promega, Southampton, UK), 1.5 mM dNTPs,
1× AMV-RT buffer and 7.5 U AMV reverse transcrip-
tase (Promega, Southampton, UK). Primers specific for
Fkbpl (musdirf5ex CTTCCAGGCCTCAACATCAT and
musdirR TCCCAGCTCGAAACAGTTCT: chr17
34781824-34782871 NCBI build 37; cDNA 756 nt; DNA
1028 nt) or b-actin (Bact1 GCTGTGCTATGTTGCTC-
TAGACTTC and Bact2 CTCAGTAACAGTCCGCCTA-
GAAGC: chr5 143665461-143666180; cDNA 500 nt;
DNA 730 nt) were supplied by Invitrogen, Paisley, UK.
All primers were checked for uniqueness and location
using the BLAT tool available at the UCSC website [22].
PCR was performed in 25 μl containing 1× Taq buffer,
200 μM dNTPs, 0.4 μM primer, 2 U Taq (Invitrogen,
Paisley, UK) and 1 μl cDNA. Initial deannealing at 94°C
for 3 min was followed by 28 cycles of 45 sec at 94°C, 1
min at 61°C, and 1 min at 72°C and a final elongation
for 5 min at 72°C. PCR products were separated on
agarose gels and images captured using a Kodak digital
camera.
RNA expression analysis using radioactive probes
A Mouse RNA Master Blot array normalised to provide
semi-quantitative data on tissue specificity and target
mRNA abundance was purchased from BD Biosciences,
Cowley, UK. Human and mouse FKBPL coding-region
probes were amplified by PCR using: HumanF
CTAGGCTCCTGCTGCCGGCTACTG and HumanR
TCAGCAGTTGCTTTTTCCAGGTCC; musdirF
GAACGAGAAGAACACCGCTC and musdirR
TCCCAGCTCGAAACAGTTCT. Northern blotting,
radiolabelling of cDNA and detection of mRNA were as
previously described [23].
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Nucleotide sequence screening of FKBPL gene
The whole FKBPL gene was directly amplified from
patient DNA using primers 5’-GGCTCCAGGGT-
TAGTTGTCA-3’ and 5’ CCCAAATCTCACAGCACA
GA-3’ and purified with the Wizard Gel PCR clean-up
kit (Promega, Southampton, UK). Sequencing was done
using primers S1 5’-AACCAGTCAGATGCCAGAGG-3’,
S2 5’-CCTCTGG CATCTGACTGGTT-3’, S3 5’-GAAC-
CAGGTTCAGGTCAGC-3’, S4 5’-GACTAG CGA-
GAAGGAAGCC-3’ and S5 5’-GGCTTCCTTCTCG
CTAGTC-3’ on an ABI Prism 3130 at the Centre for
Molecular Biosciences Sequencing Facility. Patient
sequences were compared with the REFSEQ entry and
examined for known variations using the UCSC browser
[22]. Zygosity of mutations was confirmed by sequen-
cing TOPO-TA (Invitrogen, Paisley, UK) cloned PCR
products.
Generation of expression constructs and reporter assays
N-terminal GFP-tagged constructs were generated by
cloning into pcDNA3.1/NT-TOPO-GFP (Invitrogen,
Paisley, UK) using the primers fkbplF0: GAGACCC-
CACCA CTCAATAC and fkbplR0: TCAGCCAAA-
CATCTTGCCC. LNCaP cells (4 × 104 per well) were
seeded in 24-well plates coated with fibronectin (Invitro-
gen, Paisley, UK) and maintained in phenol red-free
RPMI1640 with 10% charcoal-dextran stripped FBS and
10 mM HEPES at 5% CO2 for 24 h. Cells were then
co-transfected for 6 h using lipofectamine (Invitrogen,
Paisley, UK) with pPA6.1Luc reporter construct, GFP-
FKBPL-WTl or a pcDNA3.1 empty vector control
together with the pBIND Renilla transfection efficiency
control. The transfection mix was then replaced by the
RPMI media with or without 10 nM R1881 and lucifer-
ase activity assessed 24 h post-transfection using the
Dual-Glo assay system (Promega, Southampton, UK).
Western blot analysis
Whole cell protein extracts were obtained by lysis with
extraction buffer (50 mM Tris-HCl, 150 mM NaCl, 5
mM EDTA,10% glycerol, 1% Igepal,1% protease inhibitor
cocktail for mammalian cells (Sigma)), followed by cen-
trifugation to remove debris. A 30 μg aliquot was frac-
tionated on a 7.5% SDS-polyacrylamide gel (Biorad,
Hemel Hempstead, UK) and transferred to a nitrocellu-
lose membrane (GE Healthcare, Amersham, UK). Mem-
branes were blocked for 1 h at RT with 5% preimmune
serum in Tris-buffered saline with 0.2% Tween-20
(TBST) prior to incubation with a 1:800 dilution of anti-
FKBPL rabbit polyclonal IgG (cat. no. 10060-1-AP, Pro-
teintech Group, Chicago, USA) in TBST. After washing
with TBST, membranes were exposed to a horseradish
peroxidise (HRP) conjugated secondary antibody (sc-
3837, Santa Cruz Biotechnology, Santa Cruz, USA) and
signal detected using ECL reagents (GE Healthcare,
Amersham, UK).
Immunohistochemistry
Paraffin-embedded sections of a fertile human testis
were obtained from ProSci Inc, Poway, California, USA.
For FKBPL and FKBP52, tissue was dewaxed and rehy-
drated through an alcohol series prior to antigen retrie-
val by heating in 10 mM citrate buffer (pH 6.0) using a
600 W microwave oven (2 × 3 min). Blocking was car-
ried out with 10% serum in PBS-Tween20 (PBST) for 1
h at RT followed by 15 min with 1% hydrogen peroxide
to remove endogenous peroxidase activity. Sections were
washed twice with PBST then incubated overnight with
1:100 rabbit anti-human FKBPL (ProteinTech Group
Inc, Chicago) or 1:250 dilution of anti-FKBP52
(cat#10011442, Cayman Chemical Company, Ann
Arbor, Michigan, USA) at 4°C, followed by 1 h incuba-
tion with 1:2000 goat anti-rabbit IgG-HRP. Immunos-
taining was carried out with DAB Substrate Plus kit
(Zymed, South San Francisco, USA), before counter-
staining with hematoxylin (Sigma, Welwyn Garden City
UK), dehydrating and mounting in Mowiol (Calbiochem,
Nottingham, UK). For AR, immunostaining was essen-
tially as described previously for this antibody (PG21,
Millipore, Billerica, MA) [24], with a Vectastain ABC kit
(Vector, Peterborough, UK) used for signal amplification
and the Impact DAB kit (Vector) used for staining.
Statistical analysis
To examine differences in mutation frequencies between
patient and control groups, Chi-squared values were cal-
culated from a contingency table (Yate’s method) and
used to calculate significance values (p) by Fisher’s exact
method in the PRISM application (Graphpad, San
Diego, USA).
Results
Structure and expression
FKBPL is encoded by a small two-exon gene (Fig. 1A).
The protein contains a peptidyl-prolyl cis-trans isomerase
(PPI) domain (Fig. 1B) and a region containing tetratrico-
peptide repeats (TPR), like other members of the FKBP
family of proteins, which act as cochaperones for steroid
receptor complexes. FKBPL shows low homology over
the PPI domain and lacks critical residues that have been
shown to be required for enzymatic activity (Fig. 1C), but
is relatively well conserved at the TPR, which have been
shown to be functional in binding HSP90 [13]. The pro-
tein is highly conserved across several mammalian spe-
cies, indicative of an important function.
Screening of a normalised Mouse RNA Master Blot
array showed very high levels of expression in testis and
epididymis (Fig. 2A), high levels in submaxillary gland and
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low levels in all other tissues: this was confirmed by north-
ern blotting (Fig. 2B). RT-PCR of testis mRNA showed
that transcription of the gene is turned on during sexual
maturation in the male mouse at puberty (Fig. 2C).
Expression in humans was assessed using a similar array
which contained 75 tissue-specific polyA+ RNAs: tran-
scription was more widespread, but was again strongest in
testis (data not shown). An antibody has recently been
raised to FKBPL. We carried out immunostaining on
human testis sections to see if FKBPL is expressed here
(Fig. 3A). Staining was found in most cells of the tubule,
including the Sertoli cells, which can be distinguished by
an ovoid nucleus with a single prominent nucleolus [25].
There was no staining in the peritubular myoid cells or
blood vessels but the interstitial Leydig cells were promi-
nently stained. Staining of the same sections with an anti-
body to AR showed nuclear staining of Sertoli, Leydig and
peritubular myoid cells but no signal was visible in the
germ cells such as spermatids (Fig. 3A), as previously
reported [24]. Staining for FKBP52 gave a similar pattern
to FKBPL but with very weak or absent staining of the
Leydig cells (Fig. 3A). Staining carried out with preim-
mune serum as a negative control gave no background.
To confirm the specificity of the FKBPL antibody we car-
ried out western blotting on human cell lines carrying a
GFP-tagged version of the human protein (Fig. 3B). The
antibody detected both endogenous and transfected
FKBPL, with little or no background.
Evidence for involvement in human infertility
We found that FKBPL in humans maps to a region
linked to azoospermia in a Japanese population (LOD
score 3.5, p = 0.0005) [17]. We examined 60 of the
patient samples used in that study and 56 controls from
the same population and looked for mutations in the
FKBPL gene by direct sequencing, which we numbered
in order from the 5’ end of the gene (Table 1 and Fig.
1A). This identified two patients carrying heterozygous
mutations in the gene in the azoospermic group, one a
mutation in the canonical splice acceptor site (CAG/G
-> CGG/G) for the only coding exon, shown previously
to give loss of function [26] (mutation 3, Table 1), and
the other an insertion which is predicted to alter a bind-
ing pocket (mutation 6, Table 1). These mutations were
confirmed by cloning PCR products and sequencing
individual clones and by sequencing of blinded samples
at a second laboratory. Neither mutation was present in
our control group. We also examined a cohort of 30
patients from an Irish infertile male population where Y
chromosome microdeletions and chromosomal abnorm-
alities have been excluded and a matched control group
of 30 fertile Irish males. Two of the Irish patient sam-
ples had single amino acid changes in the coding region
(mutations 4 and 5, Table 1) which were not found in
the control group. The Japanese and Irish patients also
showed significantly different frequencies of synon-
ymous mutations at two sites compared to controls
Figure 1 FKBPL structure and conservation. A. Structure of the human and mouse genes. The gene consists of two exons, joined by a short
intron. The open reading frame is in grey, lengths in base pairs are indicated. The positions of the gene alterations seen in patients and listed in
Table 1 are indicated above the human sequence. B. Protein structure. Peptidyl-prolyl cis-trans isomerase (PPI) domains are shown in yellow,
tetratricopeptide repeats (TPR) in green. FKBP12 has a PPI domain but contains no TPR. FKBP52 and FKBP51 contain a duplication of the PPI
domain, but the C-terminal copy is inactive (X). FKBP6 and FKBPL have N-terminal regions with some homology to the PPI.C. Alignment of the
PPI domains from FKBP6, FKBP12 and FKBPL by CLUSTALW: residues conserved in PPI with good enzymatic activity are indicated above the
alignment but can be seen to be poorly conserved in FKBPL.
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(mutations 1 and 2, Table 1), suggesting that these
alterations may be functionally significant or tightly
linked to as-yet unidentified alterations elsewhere.
Possible function of FKBPL in testis
The azoospermic and infertile nature of our patient
group, combined with the expression pattern of the pro-
tein, suggested that FKBPL, like FKBP52, might be a co-
chaperone for Androgen Receptor in the testis. To
check for AR interaction, we used the androgen-respon-
sive prostate cancer cell LNCaP which have high levels
of AR. These were transfected using a reporter construct
(pPA) containing luciferase downstream of the prostate
specific antigen (PSA) transcriptional regulatory ele-
ments [9] (kind gift of Dr. J.-T. Liu). Results are shown
in Figure 3C: FKBPL enhanced AR activity on the PSA
reporter specifically in response to ligand (R1881).
These results show that FKBPL enhances transcriptional
activation by AR of a major target gene. We confirmed
this effect in mouse fibroblast cells co-transfected with
FKBPL and AR in the presence of the reporter (not
shown). In addition, we cloned the allele with the small
insertion (mutation 6, Table 1) seen in Japanese patient
83 (p83). Results with this construct were however vari-
able and while some experiments showed a marked
decrease in enhancement of AR activity, on the whole
activity of the PSA reporter in the presence of p83 pro-
tein was close to that seen with the wild-type protein
(Figure 3D: a result representative of the median of the
experiments is shown).
Discussion
We describe here a number of alterations in the FKBPL
gene which are found only in azoospermic males and
are absent in matched controls. Four patients from two
ethnic groups show different coding changes: these
Figure 2 Fkbpl transcription in mouse. A. A Multiple Tissue Array normalised polyA+ RNA blot was hybridised to a radiolabelled Fkbpl cDNA.
The locations of testis, epididymis and submaxillary gland RNA are indicated. Top row: brain (A1), eye (A2), liver (A3), lung (A4), kidney (A5);
Second row: heart (B1), skeletal muscle (B2), smooth muscle (B3), pancreas; Third row: (C1), thyroid (C2), thymus (C3), submaxillary gland (C4),
spleen (C5); Fourth row: testis (D1), ovary (D2), prostate (D3), epididymus (D4), uterus (D5); Fifth row: embryo 7 days (E1), embryo 11 days (E2),
embryo 15 days (E3) and embryo 17 days (E4); Last row: negative controls (F1-4). Positions not listed (e.g. B4) are blank. B. Northern blotting.
Total RNA (20 ug) was extracted from the tissues indicated and fractionated on a 1% gel containing formamide before transferring to
nitrocellulose and hybridising to the cDNA probe used in A. The positions of relevant size markers are indicated at right. The experiment was
repeated twice. C. RT-PCR of total RNA isolated from testis at different days postnatally. The primers span the intron, allowing any contaminating
genomic product to be easily distinguished (right); b-actin is used as an internal positive control: RT- are negative controls. The experiment was
repeated twice.
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include mutation of the splice acceptor site for the only
coding exon, a 4aa insertion in a conserved PPI binding
pocket and two amino acid changes. In keeping with a
potentially important role in male reproduction, the
gene shows strong tissue-specific expression in the
mouse testis, with transcription being initiated with
the onset of sexual maturation. The human homologue
is likewise strongly expressed in the cells of the testis.
The protein produced is a member of a steroid hormone
receptor co-chaperone family and we found the expres-
sion of FKBPL in the testis to be very similar to that of
FKBP52, an androgen receptor regulator.
Both FKBP52 and FKBP6, another family member,
have been implicated in male sexual development in
mice, but in human case:control studies no mutations
were found in either gene in azoospermic or hypospadic
males [27-29]. FKBP6 has been reported to be a struc-
tural component of the synaptonemal complex [30]: we
could confirm from reprobing our array blot that Fkbp6
was expressed in testis only, and not epididymis and
submaxillary gland where Fkbpl levels were high (data
not shown). Expression in submaxillary gland is charac-
teristic of steroid hormone signalling components [31].
Figure 3 FKBPL expression in human testis. A. Immunohistochemical staining of human testis sections with the indicated antibodies. AR
shows nuclear staining in Sertoli (Si), Leydig (L) and peritubular myoid (P) cells, but is negative elsewhere, including spermatids (Sd). FKBP52 is
cytoplasmic, staining Sertoli and spermatogenic cells, but shows weak or absent staining in Leydig and myoid cells. FKBPL is also cytoplasmic,
matching FKBP52 in most respects except for strongly staining the Leydig cells. Preimmune serum for FKBPL (shown) and other antibodies was
used as a negative control (neg.). Experiments were repeated three times. Staining for FKBPL and FKBP52 was almost identical in rat testis (not
shown). B. Western blot of total protein from untransfected HT29 cells (untransfect.) or transfected with a GFP-FKBPL fusion protein (transfect.).
The size of the endogenous protein (endog.) is indicated. The experiment was repeated three times. C. LNCaP cells were transfected with a
construct (pPA) containing luciferase driven by the prostate specific antigen transcriptional regulatory elements either with or without FKBPL as
shown. The indicated cultures were additionally exposed to 1 nM of AR ligand (R1881). Luciferase activity was measured using a fluorimeter and
normalised to an internal control. The experiment was carried out more than three times with similar results. D. LnCaP cells were transfected
with pPA and FKBPL from normal controls (WT) or from the mutated allele seen in patient 83 (p83- listed as #6 in Table 1) and exposed to
R1881. The results shown represent the median of three experiments.
Table 1 Sequence differences between azoospermic
patients and matched controlsa
Mutation Type Alteration Locationb Frequency
1 Base
change
Synonymous 32205968 0 Japanese
patients,c
12 controls
2 Base
change
Synonymous 32205869 10 Japanese
patients,d
0 controls
2f Base
change
Synonymous (as above) 8 Irish patients,e
1 control
3 Splice site Loss of
function
32205611 1 Japanese patient,
0 controls
4 Base
change
Asn=>Ser 32205453 1 Irish patient,
0 controls
5 Base
change
Thr=>Arg 32205391 1 Irish patient,
0 controls
6 Insertion 4AA
duplication
32205307 1 Japanese patient,
0 controls
aGroup sizes: Japanese patients (n = 60) and Japanese controls (n = 56); Irish
patients (n = 30) and Irish controls (n = 30).
bLocation given with respect to the International Human Genome Sequencing
Consortium March 2006 human reference sequence (NCBI Build 36.1).
cProbability p <0.001; d p = 0.0014, e p = 0.026 by Fisher’s exact test, see also
methods
fListed twice, as the frequencies and associated probabilities differ in the two
populations
Sunnotel et al. Reproductive Biology and Endocrinology 2010, 8:22
http://www.rbej.com/content/8/1/22
Page 6 of 8
Like FKBP52 [8], FKBPL appears to be expressed more
widely in testis, including in the Sertoli and Leydig cells,
than FKBP6, which is confined to the spermatogonial
stem cells only [30].
Sertoli cells are AR-producing cells located inside the
testis tubules where they play a crucial role in nurturing
and supporting the development of the spermatogonia
and act as a blood-testis barrier, as well as producing
anti-Müllerian hormone [32]. Cell type-specific knockout
of AR in Sertoli cells leads to azoospermia in mice
[10,11]. FKBP52 has been shown by two groups to act as
a cochaperone for AR and to boost AR transcriptional
activity in response to androgen [8,9]: homozygous dele-
tion in mice had no effect on the testis, but prostate and
other secondary sexual organs expressing FKBP52 were
reduced or absent. This suggests that another co-chaper-
one for AR might exist in the testis and FKBPL is
strongly expressed in Sertoli cells. It is notable that Ley-
dig cells also show strong AR and FKBPL staining (Fig.
3A and [24]) but show weak signal for FKBP52 (Fig. 3A
and [8]). Our data show that transfection of FKBPL into
the androgen-responsive human LNCaP cell line, or into
mouse fibroblasts with AR, increases signalling through
the receptor in response to ligand. This is consistent with
a role similar to that of FKBP52, except in the testis. The
fact that FKBPL can interact with GR and probably p53
in some tissues [13] also matches the multi-client protein
behaviour of FKBP52, as shown by several laboratories
[8,9,33] and with data from the Pratt and Sanchez groups
[34,35] which suggest that the co-chaperone:client pro-
tein interaction is tissue-dependent.
The type of splice acceptor mutation in patient 25 has
been shown before to result in loss of function [26] and
so is predicted to prevent FKBPL production completely
from this allele. If FKBPL forms part of a multimeric
assembly, like other cochaperones, loss of this compo-
nent might cause destabilisation of the whole complex.
The insertion mutation in patient 83 is predicted to
alter a binding pocket in the PPI domain of the FKBPL
protein, based on the crystal structure of FKBP52. In
our reporter assay, the mutated protein gave variable
results but the overall trend was for a small though not
statistically significant decrease in luciferase levels. This
decrease in AR-mediated transcription may be more
marked under physiological conditions in testis cells.
The domain is highly-conserved in mammals and
McKeen et al have recently shown that it is important
for interaction with dynamitin and subsequent nuclear
translocation of the steroid hormone:chaperone complex
[14], like the PPI domain of FKBP52 [33], so the muta-
tion also might affect this, or some other aspect of
FKBPL function which is not currently well-understood.
The frequency of alterations in FKBPL in the azoos-
permic populations is not inconsistent with the
frequencies seen for other human genes implicated in
infertility, such as Y chromosome microdeletions (2-20%
of infertile males [3]) or in particular the other autoso-
mal genes such as SYCP3 (heterozygous mutations in 2/
19 infertile males [36]); USP9 (17/576 patients or 3%
[37]) and Protamine 1 (heterozygous mutations in 1-
10% of patients [38,39]. A large number of genes contri-
bute to normal fertility, so it is expected that the indivi-
dual contributions of any one gene will be low. The
heterozygous nature of the mutations uncovered so far,
a feature of the other genes implicated in human inferti-
lity listed above and consistent with a recent screen
[30], could indicate haploinsufficiency, or that the muta-
tion on the other chromosome is as yet undetected. It is
also of note that the FKBP6 gene in humans has been
reported to be monoallelically expressed [29].
Conclusions
Linkage analysis and clustering of chromosomal break-
points in infertile males both implicate the region con-
taining the FKBPL gene in azoospermia. Here we show
that the protein, like its paralogs, can act as an AR
cochaperone and is expressed at high levels specifically
in mature testis. Azoospermic patient groups from two
populations show mutations in the gene not present in
matched controls. Overall, these results indicate that
mutations in FKBPL are associated or partially responsi-
ble for infertility in males and shed light on its expres-
sion and role in the normal testis.
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